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1. Introduction
Malignant glaucoma was described for the first time and named so by Albrecht von Graefe
in 1869 [1]. It is characterized by normal or increased IOP (intraocular pressure) associated
with axial shallowing of the entire anterior chamber in the presence of a patent peripheral
iridotomy [2,3]. The pathology is based on the existence of a block for normal flow of aque‐
ous humour, which results in the accumulation of aqueous at an improper location in the
eyeball [4]. The proposed mechanism involves a misdirection of aqueous humour passing
posteriorly into or behind the vitreous gel [5]. This is a dynamic process, and if untreated,
causes loss of vision. Local hypotensive treatment does not cause normalization of IOP, and
conventional glaucoma surgery proves to be ineffective [3].
1.1. Classification
Classification includes phakic, aphakic, and pseudophakic malignant glaucoma. Aphakic
malignant glaucoma is the onset of symptoms after a cataract surgery or the persistence of
symptoms after treatment of phakic malignant glaucoma through the cataract extraction [6].
“Non-phakic malignant glaucoma” is a general term used for both types: aphakic and pseu‐
dophakic malignant glaucoma [6]. The term malignant-like glaucoma was proposed for cases
with a known cause of forward displacement of the lens along with the frontal surface of the
vitreous body other than the “trapping” of humour inside of the vitreous body [7]. There
also exists a classification of malignant glaucoma into that occurring after surgical interven‐
tion and without such intervention [8].
The not fully known etiology of the process creates difficulties in the standardization of no‐
menclature. Certain authors suggest that the malignant glaucoma group should exclude cas‐
es in which e.g. pupillary block or choroidal detachment has been stated [9]. Others believe
that using this term to encompass a broader spectrum of eye diseases will create a better un‐
© 2013 Rękas and Krix-Jachym; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
derstanding of the pathophysiology and the relationship between pathologies with similar
clinical pictures [4].
1.2. Occurrence
According to literature, malignant glaucoma develops in 2% to 4% of patients with a his‐
tory  of  acute  or  chronic  angle-closure  glaucoma that  have  undergone  filtration  surgery
[3]. In own material, consisting of a total of 1689 penetrating and non-penetrating opera‐
tions, performed as glaucoma surgery alone or combined with cataracts, malignant glau‐
coma  occurred  in  1.3%  of  all  eyes  after  surgery.  After  penetrating  surgery  this
complication was noted in 2.3% of eyes.  It  was also observed after laser iridotomy [10],
phacoemulsification of cataract [11], posterior capsulotomy using a Nd-YAG laser (Neody‐
mium-yttrium-aluminum-garnet laser)  [12], cyclophotocoagulation [13], after implantation of
large-sized IOLs (intraocular lens) [14], after local application of miotics [15], after suturol‐
ysis [16], and even in eyes that did not undergo surgical procedures [17]. Cases of malig‐
nant  glaucoma  have  also  been  described  in  eyes  in  which  glaucoma  had  not  been
established earlier [11].
Malignant glaucoma occurs significantly more frequently after penetrating surgery than in
the case of non-penetrating surgery, after just the glaucoma surgery than after treatment
combined with phacoemulsification, as well as in eyes with narrow angle glaucoma. It was
stated with greater frequency among women, which may be related to the lesser dimensions
of the anterior segment of the eyeball in this group of patients [18]. This complication can
take place at various times after the operation, sometimes immediately, and sometimes after
one year has passed or even after a longer period of time [3].
2. Anatomical basis
It is considered that incorrect anatomical relationships lead to disruptions in the direction of
aqueous humour flow [4,19]. The place of increased resistance may be located at the level of
the iris-lens, ciliary-lens, iris-hyaloid, and ciliary-hyaloid block [4,20]. Structures that are
particularly related to the development of malignant glaucoma and its clinical picture:
Sclera – a thick sclera may lead to partial stenosis of the vortex veins, impairing normal ve‐
nous outflow and causing overfilling of the choroid [21], as stated in eyes with malignant
glaucoma [22]. Opening of the anterior chamber during surgery, which causes lowering of
IOP, together with possible movements of the irido-lenticular diaphragm can trigger a ma‐
lignant glaucoma mechanism in such eyes.
Lens – the exciting cause for malignant glaucoma in many cases is a lens that is too large for
the eye [23]. Disproportions between its volume and the volume of the entire eyeball can oc‐
cur; furthermore, particular anatomical relationships between the anterior vitreous, ciliary
processes, and the lens foster the occurrence of malignant glaucoma [4,19].
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Choroid – the choroid has a lobular structure with a tendency for accumulation of blood and
thickening when outflow is impaired. Secondary, ciliary body and iris rotate to the front in
patients with malignant glaucoma [24], closing access to the filtration angle from the back.
Vitreous body – Slit-lamp examination of the vitreous may reveal optically clear areas with‐
in the vitreous body – reservoirs of aqueous humour trapped in its gel structure [3], which
may be confirmed on ultrasound [25]. In aphakic eyes, the anterior surface of the vitreous
body may directly adhere to the ciliary processes [3].
The anterior and posterior chambers and their relationship – total obliteration of the posteri‐
or chamber by the vitreous and a highly resistant hyaloid membrane may be observed in
aphakic and pseudophakic eyes [26].
3. Predisposing factors
The anatomic and functional differences of predisposed eyes seem to be a significant factor
for determining the occurrence of malignant glaucoma. The following predisposing factors
have been described, among others: axial hyperopia [27], nanophthalmos [28], disorders of
anatomical proportions in the anterior chamber [18].
Figure 1. Normal eye, relative anterior microphthalmos and nanophthalmos.
It  is  considered that  malignant glaucoma is  related to a special  eye anatomy (small  eye
phenotype). Lynch et al. stated that it occurs more frequently in small eyes with an ana‐
tomically narrow iridocorneal angle [11]. Many nanophthalmic and RAM eyes have nar‐
row  angles  with  crowded  structures  in  the  anterior  chambers.  Typically,  the  lens  is  of
normal or increased thickness, leading to a high lens:eye ratio and this crowding results
in a shallow anterior segment that predisposes to angle-closure glaucoma [21]. In micro‐
phthalmos, due to small eye size, the increase in the size of the lens with age is critical,
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and a relative pupillary block forms with progressive shallowing of  the central  and cir‐
cumferential  anterior chamber,  narrowing,  and gradual angle closing [29].  However this
is not the only angle closing mechanism in this pathology. Peripheral iridectomy, which
eliminates pupillary block, does not prevent progressive overfilling of the choroidal bed,
which may cause further angle closure. If the aqueous humour is directed to the vitreous
cavity instead of the posterior chamber, symptoms of malignant glaucoma will occur [30].
Thus, in a genetically conditioned microphthalmos, glaucoma with a complex iris and cil‐
iary block may be expected [20].
The occurrence of malignant glaucoma in the pathology that is the microphthalmos may
not only be connected to abnormal anatomical relationships but also to incorrect histolog‐
ical structure of the sclera. The sclera in a microphthalmos is thicker relative to physiolog‐
ical  conditions  and its  collagen fibers  are  more disorganized [31].  Trelstad et  al.  stated,
that in a microphthalmos, collagen fibers of the intercellular substance in the connective
tissue of the sclera have a normal thickness, but the collagen fibers are longer, less organ‐
ized, and more interwoven [32]. Yue et al. stated that a greater heightened level of fibro‐
nectin, and speculated that a change in the glycosaminoglycan metabolism may influence
the contraction of collagen fibers and lead to thickening of the sclera. The authors believe,
that an incorrect glycosaminoglycan metabolism may cause a decrease in the elasticity of
the sclera, which hampers normal development of the eye [33]. Based on known measure‐
ments of the thickness of the sclera, increased thickness of the tissues, including the reti‐
na, choroid, and sclera in echographic measurements was considered to be a value above
1.7 mm [34]. The increased thickness of the sclera in hyperopic eyes and its simultaneous‐
ly lower surface area decrease transscleral protein transport, what, in consequence, causes
choroidal expansion [22]. According to Quigley et al.,  a similar situation occurs in many
eyes that do not achieve such small sizes, and malignant glaucoma can occur in eyes of
correct sizes as well as in small eyes, but all cases would have dramatic choroidal expan‐
sion or  vitreous  flow abnormality  [22].  In  the  case  of  a  nanophthalmos,  a  tendency to‐
ward spontaneous or postoperative uveal effusion was also observed [21]. Quigley et al.
observed that in eyes with extremely small sizes, displacement of the lens to the front oc‐
curs, caused by choroidal expansion [22]. Furthermore, the increased pressure in the vor‐
tex  veins  occurring  in  a  microphthalmos  as  well  as  disrupted  transscleral  protein
transport  and increased  oncotic  pressure  of  the  vitreous  body  may be  linked  to  an  in‐
creased risk of development of malignant glaucoma [21,22].
One of the more important factors predisposing the occurrence of malignant glaucoma is al‐
so partial or total closing of the filtration angle at the time of the surgery, especially if the
malignant glaucoma occurred in the second eye [3]. However, IOP has no direct correlation
to the risk of occurrence of malignant glaucoma. In Simmons’s studies, the IOP level during
the operation was not correlated with the probability of development of malignant glauco‐
ma after surgery [3]. Moreover, it should be pointed out, that in the case of malignant glau‐
coma in one eye, the fellow eye exhibits a predisposition for occurrence of a malignant
process [6].
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4. Pathomechanism
The causes of malignant glaucoma are complex and there are several theories on the subject
of factors that may have an influence on its development. As of now, the pathophysiological
mechanism of malignant glaucoma is not yet fully understood. There is no certainty as to
what structures or biochemical processes lead to the development of malignant glaucoma,
and its cause seems to be conditioned by many factors.
An anterior rotation of the ciliary body processes, leading to ciliolenticular touch and cil‐
iary  block,  has  been  suggested  [25].  Forward  displacement  of  a  relatively  large  lens,
which then blocks  communication between the  posterior  and anterior  chamber,  as  well
as  outlets  from the  eye,  is  the  essential  anatomical  feature  of  malignant  glaucoma [35].
Congestion of the uveal tract may play a part in pushing the lens into its forward posi‐
tion and holding it there [35]. In addition, in certain cases, the lens capsule and zonules
may constitute  a  place  of  resistance  for  the  flow of  aqueous  humour  to  the  front  [36].
The aqueous humour produced to the posterior chamber is directed to the back instead
of to the anterior chamber [5],  causing anterior displacement of the lens-iris diaphragm.
Furthermore,  swelling  of  the  ciliary  processes  caused  by  inflammation  or  miotics  can
cause critical narrowing of an already anatomically narrow space between the lens equa‐
tor and the ciliary body and relative block of forward aqueous flow [18]. Abnormal cho‐
roidal  circulation  may  also  lead  to  accumulation  of  blood  and  swelling  of  the  ciliary
processes. Moreover, Epstein and coauthors hypothesized that there is decreased perme‐
ability of the vitreous body or the anterior hyaloid to anterior flow of aqueous humour
into the anterior chamber in malignant glaucoma [37].
Probably, there are eyes with predispositions for malignant glaucoma, in which there is a
pathology of connective tissue related to a predominance of intercellular substance, mainly
comprised of glycosaminoglycans. Glycosaminoglycans produced by fibroblasts of patho‐
logical connective tissue accumulate in the vitreous of such eyes with malignant glaucoma.
Glycosaminoglycans, together with proteins gathered in the vitreous body because of im‐
paired transscleral outflow, are responsible for the increase of oncotic pressure and accumu‐
lation of water. Moreover, high viscosity caused by mucopolysaccharides content makes the
flow from the posterior to the anterior chamber more difficult. Glycosaminoglycans may al‐
so be a cause of iridocorneal angle damage.
The coexistence of anatomical and physiological predispositions and changes in IOP in the
anterior chamber during surgery, activates a specific pump mechanism caused by move‐
ments of the lens-iris diaphragm, which may have an influence on the development of ma‐
lignant glaucoma. The malignant process can have various dynamics with clinical
manifestation occurring directly after surgery, when exciting factors cannot be compensated
in the closed system of the eyeball. On the other hand, the occurrence of malignant glauco‐
ma symptoms may be delayed if a relative equilibrium between the volume of the produced
fluid and the outflow from the eyeball is reached.
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5. Objective symptoms
Myopic shift in refraction related to the anterior dislocation of the iris-lens diaphragm with
secondary improvement of near vision [38].
Narrowing or shallowing of the circumferential and central part of the anterior chamber even if
patent iridotomy or iridectomy is present. Shallowing of the anterior chamber is related to ante‐
rior dislocation of the iris-lens diaphragm [39,40] and iris-hyaloid diaphragm with coexistence
of increased IOP [40]. Persistent symptoms of malignant glaucoma lead to the formation of in‐
tensified anterior adhesions due to the long-lasting shallowing of the anterior chamber [41].
Figure 2. Axial shallowing of the anterior chamber in an eye with malignant glaucoma.
Increased IOP – intraocular pressure may increase slowly with simultaneously intensifying
shallowing of the anterior chamber [42]. It is characteristic that in the presence of an active,
well functioning filtering bleb, the increase in intraocular pressure can be moderate [43].
No decrease of IOP in response to conventional antiglaucoma treatment [4].
In many cases, a decrease of IOP or curing as a result of mydriatic-cycloplegic therapy [44].
Reaction to surgical treatment of the vitreous body [6].
6. Differential diagnosis
Glaucoma with pupillary block – pupillary block angle closure occurs when the posterior
surface of the iris, in the pupillary margin, comes in contact with the lens. The increased pu‐
pillary block obstructs the flow of the aqueous humour from the posterior chamber to the
Glaucoma - Basic and Clinical Aspects426
anterior chamber, resulting in increased pressure in the posterior chamber and forward
bowing of the peripheral iris. This closes the anterior chamber angle, obstructing the trabec‐
ular meshwork and the outflow channels with subsequent elevation of the IOP. Laser pe‐
ripheral iridotomy is the treatment of choice [45] and should be performed in all cases of
pupillary block glaucoma. In pupillary block, there should not exist axial shallowing of the
anterior chamber (movement of the IOL toward the cornea). The anterior chamber usually
remains deeper in the center than on its circumference, in contrast to malignant glaucoma,
where axial chamber shallowing also occurs. If there is axial shallowing, then fluid has
somehow moved posteriorly and the vitreous is acting to shallow the chamber [46].
Angle closure glaucoma – shallowing of the anterior chamber occurs symmetrically in both
eyes. In the affected eye, the filtration angle is closed, there is a sudden increase in IOP, and
microcystic edema of the cornea. Conjunctival injection and a medium size pupil may ac‐
company these symptoms [47]. It occurs regardless of surgery and is caused by anatomical
predisposition.
Choroidal effusion - a static condition which is observed independently of operation and
has  inflammatory  (trauma  and  intraocular  surgery,  scleritis,  following  cryocoagulation
and  photocoagulation,  chronic  uveitis,  Vogt-Koyanagi-Harada  disease)  or  hydrostatic
causes (hypotony and wound leak, dural arteriovenous fistula, abnormally thick sclera in
nanophthalmos, possibly in emmetropic or myopic eyes or associated with Hunter’s syn‐
drome). Uveal effusion should not be considered to be a distinct clinical entity but rather
a state characterized by abnormal amounts of fluid in the choroid resulting in thickening
of  the choroid,  accumulation of  fluid in the suprachoroidal  space resulting in choroidal
detachment, and in some cases, accumulation of fluid in the subretinal space, resulting in
nonrhegmatogenous retinal detachment. IOP may be normal but is often reduced in uveal
effusion secondary to inflammatory factors. An exception occurs in nanophthalmic uveal
effusion wherein IOP is normal or frequently elevated and chronic angle closure glauco‐
ma may develop [48].
Suprachoroidal hemorrhage – shallowing of the anterior chamber coexists with increased
IOP, sudden pain, and the presence of a haemorrhagic, non-serous detachment of the cho‐
roid in biomicroscopic and ultrasonographic examination. It occurs most often within 1
week after surgery, rarely later [6]. Suprachoroidal hemorrhage may be caused by bleeding
diathesis, anti-coagulants, paranasal sinusitis, or may occur spontaneously. Small supra‐
choroidal hemorrhages occurring during surgery are usually absorbed extemporaneously.
Suprachoroidal hemorrhage may be also related to postoperative hypotony, and in the late
postoperative period, may be connected to increased venous pressure or increased tension
of the abdominal press.
7. Testing
Medical history – determination of predisposing factors and early statement of symptoms
accompanying the occurrence of malignant glaucoma
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Slit lamp examination – assessment of the depth of the anterior chamber shows that there is
axial (central and peripheral) shallowing of the anterior chamber and, unlike in pupil block,
the iris is not typically bowed forwards, and anterior lens movement is noted. Patency of the
iridotomy, if such exists, should be evaluated – if there is no iridotomy or the patency is in
doubt, laser iridotomy can be performed or repeated to rule out pupil block, but it does not
cause resolution of the condition. Seidel test should be performed to exclude filtering bleb
leaking after filtration surgery. Biomicroscopy assessment of the posterior segment is neces‐
sary for the purpose of ruling out choroidal detachment or suprachoroidal hemorrhage
Tonometry – usually reveals increased IOP
Ultrasonography – conducted for the purpose of determining the axial length of the eyeball
(which tends to be shorter than normal) and to determine the position and size of the ciliary
body and its processes [25]. Moreover, information on the thickness of the choroid may be
obtained through ultrasonographic examination
Ultrabiomicroscopy (UBM) – this test gives images of the iris, the intraocular lens and ciliary
body as well as their relative positions before and after the occurrence of malignant glauco‐
ma. The rotation of the ciliary body to the front and shallowing of the anterior chamber may
be subject to normalization after tearing of the anterior hyaloid [24]. This test enables visual‐
ization of the structures of the anterior segment, although the capability of conducting tests
in the early postoperative period is limited due to the immersion technique
Figure 3. OCT of the anterior segment in malignant glaucoma – shallowing of the anterior chamber, peripheral irido‐
corneal touch, forward shift of the IOL.
Anterior segment OCT (optical coherence tomography) – a non-invasive high resolution techni‐
que that can be used for the purpose of objective imaging of the iridocorneal angle structure
as well as for qualitiative and quantitative assessment. Parameters such as: AOD – anterior
chamber opening distance, ACA – anterior chamber angle have been adapted from ultrasound
biomicroscopy for the OCT method. Measurements of scleral thickness, CCT – central corneal
thickness, and central depth of the anterior chamber during an episode of malignant glauco‐
ma can also be conducted. Marked displacement of the structures of the anterior segment,
peripheral irido-corneal touch, and forward shift of the lens may be noted Examination may
reveal a decreased anterior chamber angle with extreme shallowing of the anterior chamber
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depth during the acute malignant glaucoma phase and an increase of ACA and AOD quan‐
titative values after effective treatment of this condition. It is helpful to objectively evaluate
the structures of the anterior chamber or to monitor changes in the anterior segment after
surgery. Since the presence of corneal oedema is an indication of prompt surgical interven‐
tion it can be used to assess this parameter in a non-contact fashion [40].
8. Treatment
8.1. Conservative treatment
The goal of conservative treatment is to decrease the production of aqueous humour and
shrink the vitreous while simultaneously decreasing resistance in the path of aqueous hu‐
mour flow to the anterior chamber through applied cycloplegia.
The active mechanism of the drugs used in the treatment of malignant glaucoma is as fol‐
lows:
Mydriatics – cycloplegics – paralysis of the ciliary muscle, widening of the ciliary processes
ring, tightening of the zonule apparatus, backwards movement of the lens.
Osmotically active agents – increase of blood osmolality causing movement of water from
the eyeball in the direction of hyperosmotic plasma, which results in a decrease of the hy‐
dration of the vitreous body and makes it possible to retract the iris-lens diaphragm and
deepen the anterior chamber.
β-blockers – suppression of aqueous humour production, as a result of which the volume of
humour directed towards the vitreous is reduced.
Carbonic anhydrase inhibitors – reduction of secretion of aqueous humour by inhibiting
carbonic anhydrase activity in the epithelium of the ciliary body.
Corticosteroids – by limiting inflammation, they reduce edema in the area of the ciliary
body and help to minimize inflammatory adhesions of the lens or vitreous body with the
ciliary body [20].
According to data from the literature, approximately 50% of patients react to medical thera‐
py [3]. In the work of Debrouwere et al., however, the percentage of recurrences after con‐
servative treatment of patients with malignant glaucoma was equal to 100%, despite an
initially good response to such therapy [49]. Also, in own experience, a lack of success in re‐
versing the pathogenic mechanism by means of conservative treatment in malignant glauco‐
ma concerns the great majority of cases. In own material, reactions to conservative treatment
were observed in 5 eyes with malignant glaucoma out of 22 of those tested [22.7%), howev‐
er, ultimately, a surgical procedure was necessary in three of them due to the recurrence of
typical symptoms and no control over IOP. Permanent improvement after pharmacological
treatment was achieved in only 2 eyes [9.1%). The observations of other authors also confirm
transient effectiveness of medical therapy during the initial period [11,42]. Even if IOP con‐
Malignant Glaucoma
http://dx.doi.org/10.5772/53979
429
trol is achieved as a result of such treatment, long-term cycloplegia is necessary to maintain
this effect in many eyes [25]. In some cases, when medications are discontinued or changed,
tendencies of recurrence of malignant glaucoma symptoms are observed [50]. Therefore,
medical treatment is thought to be of temporary effect and is used until definite treatment
with laser iridotomy, posterior capsulotomy and hyaloidotomy is performed. The currently
valid regimen for conservative treatment includes locally applied: atropine, phenylephrine,
β-blockers, acetazolamide, and generally administered 50% glicerol solution in oral doses
and intravenously administered mannitol. Locally applied corticosteroids play the role of
limiting the accompanying inflammatory process. If improvement has been achieved, the
dosage of hyperosmotic agents can be decreased, followed by carbonic anhydrase inhibitors,
however treatment with mydriatic-cycloplegic agents should be continued [3]. The follow‐
ing treatment schedule can also be applied: mannitol 2 g per kg intravenously once or twice
a day, acetazolamide 250 mg tid, and locally: 1% Tropicamide qid, Cosopt (dorzolamide hy‐
drochloride-timolol maleate ophthalmic solution) bid, 0.1 % Dexamethasone phosphate tid.
This regimen is usually successful until laser treatment is performed.
8.2. Surgical treatment
8.2.1. Laser treatment
Laser  therapy is  usually  used together  with  conservative  treatment  and should  be  per‐
formed as early as possible because postponement of this therapy may lead to increased
IOP with injury to the optic nerve and loss of visual field as a consequence, flattening of
the  anterior  chamber,  corneal-lens  touch,  and  corneal  decompensation.  This  method  of
management can also be used after malignant glaucoma surgery,  and then can serve to
sustain or restore the effects  of  the operation.  The main limitation of  laser  techniques –
excluding transscleral cyclophotocoagulation with a diode laser – is their dependency on
corneal transparency. Topical glycerol may lead to temporary clearance of corneal edema
and make the procedure viable.
In cases of suspected malignant glaucoma, pupillary block should be eliminated as a pos‐
sible contributory element to the shallow anterior chamber by assessing the size and pa‐
tency of iridotomy, when present,  or by the creation of a patent iridotomy, if  necessary
[51]. Surgeons may prefer to use the Nd-YAG laser alone or argon laser pre-treatment fol‐
lowed  by  the  Nd-YAG  laser.  With  an  Nd-YAG  laser  energy  of  2-5  mJ,  1-3  pulses  per
burst are usually used.
Currently, as the treatment of choice in aphakic and pseudophakic eyes, several laser effects
are used in combination: laser iridotomy with anterior hyaloidotomy and posterior capsu‐
lotomy, all through the same location. In this case, a positive effect of laser therapy is the
creation of direct communication between the vitreous, the posterior chamber, and the ante‐
rior chamber, and such a procedure can restore normal dynamics of aqueous humour flow
in malignant glaucoma [52]. If needed, it may be applied in more than one location.
Capsulotomy is usually performed using an energy of 1 to 4 mJ per pulse. The energy and
pulses may be increased gradually according to the thickness of the capsule until an open‐
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ing is achieved. 5-15 bursts with an energy of 1-3 mJ through iridotomy or iridectomy are
usually effective in achieving communication. An immediate effect of such a procedure is
often observed in the form of deepening of the anterior chamber. If there is no access to the
iridectomy, communication can be achieved through the lens capsule in a pseudophakic eye
using an energy of 1 mJ near the edge of the IOL. Such a procedure may be preceded by
decompressing the vitreous chamber by puncturing it with a 25 gauge needle through pars
plana. The above scheme may be repeated. The magnitude and patency of communication
between the anterior and posterior segments of the eye are decisive to the distribution of
pressure between the anterior and posterior segment of the eyeball. Recurrences may occur
even when communication is present but is not effective enough to decrease the force shift‐
ing the iridolenticular diaphragm forward. In the case of difficult access to the circumferen‐
tial part of the lens capsule in the area of iridectomy, the effect of deepening of the anterior
chamber is to be achieved by creating a capsulotomy within the pupil or outside the edges
of the artificial lens, after which a capsulotomy in the area of the iridectomy that is as large
as possible should be created.
The goal of Nd-YAG laser hyaloidotomy, in turn, is to tear the anterior hyaloid face, as a
result of which the depth of the anterior chamber is normalized [24]. Epstein and others
treated aphakic and pseudophakic eyes with an energy of 3 to 11 mJ delivered to the anteri‐
or hyaloid face [53]. This treatment can be conducted through surgical iridectomies or laser
iridotomies, often in many places. It is carried out centrally, to the back of the lens capsule,
or in combination with capsulotomy in pseudophakic patients [46].
Figure 4. Anterior segment OCT in eye with malignant glaucoma – complication after Nd-Yag laser capsulotomy with
hyaloidotomy - hyaloid gets across the iridotomy into the anterior chamber (white arrow); note shallow anterior
chamber, forward movement of the IOL and iridocorneal touch at considerable area.
Transscleral  cyclophotocoagulation  is  a  procedure  with  different  applications.  The  laser
beam causes ablation of the ciliary body, which causes reduction of aqueous humour se‐
cretion.  Energy absorption by melanine leads to  thermal  coagulation and destruction of
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the pigment epithelium and accompanying vessels. Deep coagulative necrosis of the pig‐
ment epithelium, pathological  reconstruction of  collagen fibers  in the stroma,  and intra‐
vascular  coagulation in  the blood vessels  of  the ciliary body take place  [43].  Significant
complications  include  postoperative  inflammation,  pain,  cystoid  macular  edema,  and
phthisis.  Thus,  indications  for  cyclophotocoagulation  are  generally  limited  to  patients
whose glaucoma has been resistant  to medical  and surgical  therapies,  with no potential
for improvement in visual acuity.
8.2.2. Surgical treatment
The indication for surgical intervention is a lack of effectiveness of conservative and laser
treatment [11,36]. An operative procedure should not be conducted too late due to the de‐
velopment of complications resulting from the persistence of the malignant process.
Figure 5. A,B: Advanced stage of malignant glaucoma - shallow anterior chamber, corneal oedema and posterior syn‐
echiae in pseudophakic eye.
Currently used methods of surgical treatment were introduced when the role of the patholo‐
gy of the anterior segment and the vitreous body in the pathogenesis of the malignant proc‐
ess were discovered. As of now, surgical intervention in malignant glaucoma is directed
towards lowering IOP, achieving correct anatomical relationships between the vitreous
body, lens, and ciliary body, and additionally enabling correct flow of aqueous humour
from the posterior segment to the anterior chamber of the eye. Achievement of communica‐
tion seems to be necessary, because the disruption of aqueous humour flow in malignant
glaucoma can last even after PPV [54]. The concept of such a procedure is based on the ob‐
servation of regression of the symptoms of malignant glaucoma in the case of direct commu‐
nication between the vitreous cavity and anterior chamber being ensured [25]. The
iridectomy may be performed using Vannas scissors or a vitrectomy tip, whereas the poste‐
rior capsulotomy and hyaloidotomy may be done with a vitrectomy tip. The anterior cham‐
ber may be reformed with air. All of these procedures should be performed in one setting
through the same location. Additionally synechiolysis may be performed if the iridocorneal
angle is completely closed using a spatula or a viscoelastic agent. The performance of all
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three steps will usually result in complete resolution of the condition. Pars plana vitrectomy
is reserved for cases that did not respond to the procedure above, and in any case, it should
be combined with opening of the anterior hyaloid face. Thus, in refractory malignant glau‐
coma, partial PPV should be performed and supplemented by procedures making it possi‐
ble to achieve communication between the anterior chamber and the vitreous cavity.
Achievement of correct flow and equalization of pressure between the posterior and anteri‐
or segment of the eyeball is decisive for the effectiveness of the surgery. Partial PPV should
be conducted conservatively, preferably using trocars and a 25 gauge vitrectome. Communi‐
cation between the anterior chamber and vitreous cavity may be achieved by cutting out the
lens capsule using a vitrectome or puncturing it through the cornea with a needle, alterna‐
tively by cutting the anterior and posterior capsules with cystotome from the side of the an‐
terior chamber within iridectomy.
Figure 6. Combined partial pars plana vitrectomy with capsulotomy communicating anterior chamber and vitreous
cavity in surgical treatment of malignant glaucoma: A. The trocar is inserted through pars plana 3.5 mm posteriorly to
the corneal limbus before PPV. B. Achieving communication between the anterior chamber and vitreous cavity using a
vitrectome.
9. Prognosis
Malignant glaucoma remains a difficult clinical problem that results in irreversible blindness
if treatment is delayed and not adequate. The surgeon should be aware preoperatively of
eyes at risk and observe them closely during follow-up visits. Early recognition is the most
important step to prevent irreversible loss of vision. The prognosis depends on the duration
and the severity of the malignant glaucoma attack. In patients with glaucoma in its early
stage, the prognosis can be good if the attack is discontinued and IOP is well controlled. The
problem is that malignant glaucoma is often resistant to conservative treatment, and laser
procedures are not always effective as well. Partial pars plana vitrectomy combined with
capsulotomy communicating the anterior chamber and vitreous cavity in such cases is an ef‐
ficacious method of intervention when it comes to IOP control, postoperative BCVA, and re‐
duction of the number of antiglaucoma medications. The prognosis after laser and surgical
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treatment depends on the occurence of complications after performed procedures. Compli‐
cations after malignant glaucoma surgery observed in own material included: increased IOP
during the early post-operative period (above 21 mmHg) [5%), inflammatory effusion [5%),
hyphema [10%), occurrence of posterior adhesions [5%), no effectiveness of filtration sur‐
gery preceding the occurrence of malignant glaucoma [55%), macular edema [10%), and reti‐
nal detachment [5%). Recurrence of malignant glaucoma with the full range of symptoms
was observed in 15% of eyes subjected to surgery. In the case of post-operative shallowing
of the anterior chamber, it is possible to conduct a capsulotomy through iridectomy, and the
use of an Nd-YAG laser for this purpose is a safe and effective method in most cases.
10. Summary and conclusions
The condition continues to be one of the most difficult types of secondary glaucoma to man‐
age. The diagnosis, definition, pathomechanism, and procedure in the case of malignant
glaucoma still give rise to controversy. The currently applied treatment has the goal of un‐
burdening the anterior chamber during the early period of the malignant process and to cre‐
ate communication between the anterior chamber and the vitreous. This is the result of the
assumption, that in the case of a lack of communication through the iridotomy, recurrence
of the malignant process can be expected after vitrectomy. New modifications of surgical
procedure may increase operative effectiveness and improve the long-term results of ap‐
plied procedures.
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